Skip to main content
. Author manuscript; available in PMC: 2015 Jul 6.
Published in final edited form as: Nature. 2014 Jul 27;513(7516):65–70. doi: 10.1038/nature13485

Extended Data Figure 3. a–j) Toxicity studies with (±)-CR-31-B.

Extended Data Figure 3

Mean and standard deviation are shown, n = 2 biological replicates. a) Animal weights during and after CR treatment (intraperitoneal injection, 0.2 mg/kg on days indicated by red arrows), red = CR, black = vehicle; b–d) Counts of white blood cells (b), red cells (c), and platelets (d) 14 days after cessation of CR treatment, blue lines indicate the species and strain specific reference range, n.s. indicates not significant, n = 2 biological replicates; e) Representative histology of gastrointestinal tract (small intestine) on the indicated days during (n = 4) and after (n = 2) (±)-CR-31-B treatment; f–j) Serum levels of alanine aminotransferase (ALT) (f), aspartate transaminase (AST) (g), albumin (h), total bilirubin (i), and creatinine (j) two weeks after cessation of treatment with CR or vehicle, blue lines indicate the species and strain specific reference range, n.s. indicates not significant.